STING1 and STING-associated vasculopathy with onset in infancy: Downstream signaling inhibition through JAK inhibitors (such as ruxolitinib, baricitinib, and tofacitinib) has been particularly successful in monogenic interferonopathies like STING-associated vasculopathy (SAVI), where they improved systemic and pulmonary manifestations [191].